Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.2.3.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.2.3.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.2.3.5NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.2.3.5NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.2.3.5ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.9.5ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.9.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.9.5NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.9.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.9.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.9.5NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.9.5NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.9.5ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FE.1.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FE.1.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FE.1.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FE.1.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FE.1.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FE.1.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FE.1.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FE.1.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.16.13ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.16.13ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.16.13NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.16.13NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.16.13NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.16.13NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.16.13NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.16.13ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FR.1.4ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FR.1.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FR.1.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-12683.7China
FR.1.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FR.1.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FR.1.4NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FR.1.4NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FR.1.4ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
GY.2.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
GY.2.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GY.2.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
GY.2.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GY.2.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GY.2.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
GY.2.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
GY.2.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBC.1.6ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBC.1.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBC.1.6NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-21977.3China
XBC.1.6NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBC.1.6NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used